ArticleAnnals of surgical oncology2026
Differential Diagnosis of Solitary Pulmonary Nodules in Postoperative Pancreatic Cancer Patients Using KRAS Gene Mutation Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSolitary pulmonary nodules in postoperative pancreatic cancer patients pose a diagnostic challenge in distinguishing primary lung cancer (PLC) from pulmonary metastasis (PM). KRAS mutation analysis is a potential tool for distinguishing these entities.
methodsA retrospective study of 17 patients who underwent pulmonary resection after pancreatic cancer surgery was conducted. Paired pancreatic and pulmonary tumor samples were analyzed for KRAS mutations. PDX1 expression was assessed by immunohistochemistry. Preoperative clinical factors were evaluated using KRAS mutation-based classification as the reference.
resultsKRAS mutations were discordant between pancreatic and pulmonary tumors in nine patients (53%), leading to a diagnosis of PLC. KRAS G12R concordance was observed in three cases, confirming PM. Five cases with KRAS G12D or G12V concordance could not be definitively classified. KRAS mutation analysis identified more PLC cases than pathological diagnosis. PDX1 expression was found in both PM and some PLC cases, as well as in lung invasive mucinous adenocarcinoma cases without pancreatic cancer history, limiting its diagnostic value. Lymphovascular invasion in the pancreatic tumor was significantly associated with PM.
conclusionsKRAS mutation analysis of both pancreatic tumor and lung tumor is useful for distinguishing solitary pulmonary nodules in postoperative pancreatic cancer patients. KRAS mutation analysis identified PLC more frequently than conventional pathological diagnosis.
Indexed as
Identifiers
41193825What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.